Assembly Biosciences
Hassan Pajouhesh, currently serving as Senior Director Medicinal Chemistry at Assembly Biosciences, Inc., has a strong background in chemistry with extensive experience in various roles at companies like SiteOne Therapeutics Inc., Neuromed Pharmaceutical, and Precision Biochemicals/IGT Pharma. With a Ph.D. in Organic Chemistry from the University of Missouri-Kansas City, a Bachelor of Science in Chemistry from the University of Utah, and postdoctoral experience in Synthetic Organic Chemistry from Southern Methodist University, Hassan's expertise and leadership have been valuable assets throughout their career.
Assembly Biosciences
9 followers
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets.